Pharmaceutical industry – Page 30
-
FeatureHow ketamine could help treat severe depression
Nina Notman looks at how the party drug ketamine may hold the key to treating patients with severe depression
-
OpinionOutlines of ignorance
There’s a lot about chemistry that we just don’t understand very well yet
-
OpinionCollaboration and competition can both stimulate innovation
Diverse approaches suit different goals
-
BusinessCrispr patent ruling breaks deadlock
Both sides claim victory as board rules patents do not interfere with each other
-
Business$2bn Immunomedics–Seattle Genetics deal delayed amid shareholder infighting
Major investor venBio seeks to derail deal and replace board members
-
FeatureDeal or no deal?
Clare Sansom highlights recent changes in the landscape of pharma company collaborations and acquisitions
-
BusinessUniversity–industry collaborations aspire to pharmaceutical innovation
Three new UK partnerships illustrate drug research co-operation approaches that are growing in popularity
-
BusinessAllergan to buy fat-freezing firm Zeltiq
$2.5bn deal adds to firm’s cosmetic and aesthetic treatments
-
BusinessDaiichi Sankyo to close R&D sites in India and Japan
Closures are part of an ongoing reorganisation aimed at increasing productivity
-
BusinessUS biotech leaders protest immigration ban
Donald Trump’s suspended order would endanger America’s biotech industry if re-instated
-
BusinessLilly buys CoLucid for migraine drugs
US firm also laying off 485 sales staff after Alzheimer’s drug failure
-
BusinessMerck & Co settles cancer antibody patent dispute
US firm will pay Bristol-Myers Squibb and Ono $625m plus royalties on future sales of immunotherapy
-
BusinessTeva hit with fines and patent loss
Double whammy as firm settles subsidiary pay-for-delay suit and courts invalidate patents on multiple sclerosis drug
-
BusinessJ&J to buy Actelion for $30bn
Actelion’s R&D will spin out as a new company, while Janssen will take on in-market and late-stage medicines
-
BusinessBiogen pays $1.25bn to protect multiple sclerosis drug sales
Agreement with Forward Pharma gives Biogen license to keep selling blockbuster Tecfidera
-
OpinionDrug regulation is a burden worth bearing
Calls to break down regulatory barriers show a misunderstanding of the industry
-
Business
Novartis on winter deal spree
Swiss company aims to re-stock drug pipeline with three new deals in skin, eye and cardiovascular health
-
ResearchDrug binding simulations promise to get personal
Fast, reliable new molecular dynamic simulation methods set to speed up research are under investigation by GSK
-
BusinessCholesterol drug withdrawn in patent dispute
Ruling that Regeneron’s Praluent antibody infringes Amgen’s Repatha patent could stifle innovation
-
BusinessIpsen to buy Merrimack’s cancer drugs
$1bn deal covers two liposome-encapsulated formulations of approved therapies